Science & Enterprise subscription

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Allergan, AstraZeneca Partner on Drug-Resistant Bacteria

(Centers for Disease Control and Prevention)

29 January 2016. Pharmaceutical companies Allergan and AstraZeneca are developing a new treatment for infections caused by a type of bacteria already resistant to antibiotics. Financial aspects of the collaboration between the enterprises were not disclosed.

The agreement calls for the two companies to develop and commercialize ATM-AVI, . . . → Read More: Allergan, AstraZeneca Partner on Drug-Resistant Bacteria

FDA Approves Nasal Spray Migraine Therapy

(geralt, Pixabay)

29 January 2016. The Food and Drug Administration approved a treatment for migraine headaches delivered as a powder sprayed into the nose. The therapy, marketed as Onzetra by Avanir Pharmaceuticals, is a formulation of sumatriptan, an approved oral drug for treating migraine symptoms.

Migraine is a neurological syndrome causing severe headaches along . . . → Read More: FDA Approves Nasal Spray Migraine Therapy

Electronic Patch Shown to Help Relieve PTSD, Depression

Neuromodulation patch and signaling device (University of California, Los Angeles)

28 January 2016. An electronic device stimulating nerves in the brain was shown in a small clinical study to relieve symptoms associated with post-traumatic stress disorder, or PTSD, and depression. The team developing the patch and taking it to market published results of the . . . → Read More: Electronic Patch Shown to Help Relieve PTSD, Depression

$100K Challenge Seeks Reinvented Clinical Trials

(PublicDomainPictures, Pixabay)

28 January 2016. A challenge at Harvard Business School seeks proposals for better ways of conducting clinical trials that bring to market faster new precision diagnostics and therapies. The competition has a total prize purse of $100,000 and an initial deadline of 13 March 2016.

Precision medicine is the term given to . . . → Read More: $100K Challenge Seeks Reinvented Clinical Trials

Eye Disease Gene Defect Repaired with CRISPR

(NIH.gov)

27 January 2016. Gene editing techniques repaired a defective gene in stem cells from an individual with retinitis pigmentosa, an inherited eye disease. The team from Columbia University and University of Iowa reported its findings in today’s (27 January) issue of Scientific Reports.

Retinitis pigmentosa is a family of genetic eye disorders that . . . → Read More: Eye Disease Gene Defect Repaired with CRISPR

Purdue Licenses Food Pathogen Fingerprint Technology

E. coli bacteria (National Institute of Allergy and Infectious Diseases)

26 January 2016. A lab equipment company is licensing a laser-based technology developed at Purdue University that quickly identifies foodborne pathogens. Financial aspects of the agreement between Purdue, in West Lafayette, Indiana and Andreas Hettich GmbH in Tuttlingen, Germany were not disclosed.

Hettich is . . . → Read More: Purdue Licenses Food Pathogen Fingerprint Technology

Material Hides Beta Cell Transplants From Immune Reaction

(Centers for Disease Control and Prevention)

26 January 2016. Engineering and biochemical researchers developed a material that in lab animals holds and protects transplanted pancreatic beta cells against an immune reaction, a key advance in treatments for individuals with type 1 diabetes. Teams from Massachusetts Institute of Technology and other institutions published their findings . . . → Read More: Material Hides Beta Cell Transplants From Immune Reaction

Business-Academic Coop to Fund Translational Research

Pharmaceutical testing lab (AstraZeneca)

25 January 2016. Three pharmaceutical companies and three universities in the U.K. are forming an independent consortium to support academic research leading to new therapies. The £40 million ($US 57 million) Apollo Therapeutics Fund will be financed by contributions from global pharmaceutical enterprises AstraZeneca, GlaxoSmithKline, and Johnson & Johnson, for . . . → Read More: Business-Academic Coop to Fund Translational Research

Safety, Activity Assessed in New Duchenne Drug

Cross-section of muscle tissue from a person with Duchenne muscular dystrophy shows extensive replacement of dark colored muscle fiber with light-colored adipose or fat cells. (Centers for Disease Control and Prevention)

25 January 2016. An early-stage clinical shows an experimental drug for Duchenne muscular dystrophy is safe for patients and produces the desired chemical . . . → Read More: Safety, Activity Assessed in New Duchenne Drug

Technique Devised to Improve Stem Cell Harvesting

Human embryonic stem cell colony (National Institute of General Medical Sciences)

22 January 2016. Researchers at the Max Delbrück Center for Molecular Medicine in Berlin developed a technique making it easier to detect stem cells and keep active longer in a cell culture. The team from the lab of molecular biologist Zsuzsanna Izsvák published . . . → Read More: Technique Devised to Improve Stem Cell Harvesting